Literature DB >> 33383293

The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review.

Bethea A Kleykamp1, McKenzie C Ferguson2, Ewan McNicol3, Ida Bixho4, Lesley M Arnold5, Robert R Edwards6, Roger Fillingim7, Hanna Grol-Prokopczyk8, Dennis C Turk9, Robert H Dworkin10.   

Abstract

Fibromyalgia (FM) is a chronic widespread pain condition that overlaps with multiple comorbid health conditions and contributes to considerable patient distress. The aim of this review was to provide a systematic overview of psychiatric and chronic pain comorbidities among patients diagnosed with FM and to inform the development of recommendations for the design of clinical trials. Thirty-one, cross-sectional, clinical epidemiology studies that evaluated patients diagnosed with FM were included for review. None of the reviewed studies reported on the incidence of these comorbidities. Sample size-weighted prevalence estimates were calculated when prevalence data were reported in 2 or more studies for the same comorbid condition. The most prevalent comorbidity across all studies reviewed was depression/major depressive disorder (MDD) with over half of the patients included having this diagnosis in their lifetime (weighted prevalence up to 63%). In addition, nearly one-third of FM patients examined had current or lifetime bipolar disorder, panic disorder, or post-traumatic stress disorder. Less common psychiatric disorders reported included generalized anxiety disorder, obsessive compulsive disorder, and specific phobias (agoraphobia, social phobia). There were fewer studies that examined chronic pain comorbidities among FM patients, but when evaluated, prevalence was also high ranging from 39% to 76% (i.e., chronic tension-type or migraine headache, irritable bowel syndrome, myofascial pain syndrome, and temporomandibular disorders). The results of the review suggest that depression and chronic pain conditions involving head/jaw pain and IBS were elevated among FM patients compared to other conditions in the clinic-based studies. In contrast, anxiety-related disorders were much less common. Addressing the presence of these comorbid health conditions in clinical trials of treatments for FM would increase the generalizability and real-world applicability of FM research.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Central Sensitization; Clinical Trial Design; Co-morbidities; Fibromyalgia; Psychiatric Disorders

Mesh:

Year:  2020        PMID: 33383293     DOI: 10.1016/j.semarthrit.2020.10.006

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  14 in total

1.  Comprehensive Preclinical Assessment of Sensory, Functional, Motivational-Affective, and Neurochemical Outcomes in Neuropathic Pain: The Case of the Sigma-1 Receptor.

Authors:  Beatriz de la Puente; Daniel Zamanillo; Luz Romero; Alicia Carceller; José Miguel Vela; Manuel Merlos; Enrique Portillo-Salido
Journal:  ACS Pharmacol Transl Sci       Date:  2022-03-17

Review 2.  The puzzle of fibromyalgia between central sensitization syndrome and small fiber neuropathy: a narrative review on neurophysiological and morphological evidence.

Authors:  Marina de Tommaso; Eleonora Vecchio; Maria Nolano
Journal:  Neurol Sci       Date:  2022-01-14       Impact factor: 3.307

3.  Patients With Fibromyalgia, Depression, and/or Anxiety and Sex Differences.

Authors:  Marcela Henao-Pérez; Diana Carolina López-Medina; Alejandra Arboleda; Sara Bedoya Monsalve; Julián Andrés Zea
Journal:  Am J Mens Health       Date:  2022 Jul-Aug

Review 4.  Fibromyalgia and Depression: A Literature Review of Their Shared Aspects.

Authors:  Daniela Yepez; Xavier A Grandes; Ramya Talanki Manjunatha; Salma Habib; Sai Lahari Sangaraju
Journal:  Cureus       Date:  2022-05-11

Review 5.  Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review.

Authors:  Antonia Klein; Christoph J Schankin
Journal:  Headache       Date:  2021-09-27       Impact factor: 5.311

6.  Cognitive-Behavioral and Personal Construct Therapies for Depression in Women with Fibromyalgia: A Randomized Controlled Trial.

Authors:  Mari Aguilera; Clara Paz; Marta Salla; Victoria Compañ; Joan Carles Medina; Leticia Medeiros-Ferreira; Guillem Feixas
Journal:  Int J Clin Health Psychol       Date:  2022-02-23

7.  Pain Burden in Post-COVID-19 Syndrome following Mild COVID-19 Infection.

Authors:  Indre Bileviciute-Ljungar; Jan-Rickard Norrefalk; Kristian Borg
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

8.  A history of depression in patients attending a chronic pain management clinic in South Africa: A retrospective chart review.

Authors:  Joseph J van Vreede; Romy Parker; Janieke van Nugteren
Journal:  S Afr J Psychiatr       Date:  2022-04-29       Impact factor: 1.242

9.  Patient Perspectives of Disease Activity, Medications and Substance Use in People with Fibromyalgia.

Authors:  Thomas Khoo; Catherine L Hill; Elizabeth Hoon; Samuel Whittle
Journal:  Open Access Rheumatol       Date:  2022-05-05

Review 10.  The Efficacy of Vitamin D Supplementation in the Treatment of Fibromyalgia Syndrome and Chronic Musculoskeletal Pain.

Authors:  Mauro Lombardo; Alessandra Feraco; Morena Ottaviani; Gianluca Rizzo; Elisabetta Camajani; Massimiliano Caprio; Andrea Armani
Journal:  Nutrients       Date:  2022-07-22       Impact factor: 6.706

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.